document.write(' \n \n

\n \n \n 09/07/10 \n \n \n Positive Results from Phase II VTE Prophylaxis Study with TB-402 (Anti-Factor VIII) Presented at the 21st Int. Congress on Thrombosis in Milan, Italy \n \n
\n \n \n 17/05/10 \n \n \n BioInvent and ThromboGenics to Receive €10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403 \n \n
\n \n \n 06/05/10 \n \n \n BioInvent and ThromboGenics Announce Positive Topline Results from Phase II VTE Prophylaxis Study with Anti-Factor VIII (TB-402) \n \n
\n \n \n 20/04/10 \n \n \n BioInvent International AB Annual General Meeting \n \n
\n \n \n 20/04/10 \n \n \n BioInvent focuses manufacturing operations on proprietary product development \n \n
\n \n \n 18/03/10 \n \n \n Annual General Meeting in Bioinvent International AB \n \n
\n \n \n 11/03/10 \n \n \n BioInvent and Human Genome Sciences Announce Collaboration to Co-develop and Commercialize Therapeutic Antibodies \n \n
\n \n \n 26/02/10 \n \n \n New number of shares and votes in BioInvent International AB (publ) \n \n
\n \n \n 02/02/10 \n \n \n Extraordinary General Meeting Approved Directed New Share Issue \n \n
\n \n \n 14/01/10 \n \n \n BioInvent announces a directed new share issue of SEK 150 million \n \n
\n \n \n 04/01/10 \n \n \n First Patient treated in BioInvent\'s Phase I Study of the Drug Candidate BI-505 to Treat Multiple Myeloma \n \n
\n \n \n 19/11/09 \n \n \n BioInvent and ThromboGenics Win “Licensing Deal of the Year” at the Scrip Awards 2009 \n \n
\n \n \n 16/11/09 \n \n \n BioInvent and ThromboGenics Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients with Advanced Solid Tumours \n \n
\n \n \n 13/11/09 \n \n \n BioInvent signs licensing agreement with Daiichi Sankyo for the discovery and development of therapeutic antibodies \n \n
\n \n \n 28/10/09 \n \n \n BioInvent and ThromboGenics Complete Patient Recruitment of Phase II DVT Prophylaxis Study with Anti-Factor VIII (TB-402) \n \n
\n \n \n 23/09/09 \n \n \n BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402 \n \n
\n \n \n 11/08/09 \n \n \n BioInvent Announces Approval to start Phase I Trial for BI-505 in Multiple Myeloma \n \n
\n \n \n 31/07/09 \n \n \n BioInvent signs Licensing Agreement with Mitsubishi Tanabe Pharma Corporation for the Discovery and Development of Therapeutic Antibodies \n \n
\n \n \n 03/07/09 \n \n \n BioInvent and ThromboGenics Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study with TB-402 \n \n
\n \n \n 20/05/09 \n \n \n BioInvent Appoints Head of Preclinical Research \n \n
\n \n \n 06/05/09 \n \n \n BioInvent Reports Positive Phase I Results for BI-204, in development for prevention of cardiovascular conditions associated with atherosclerosis \n \n
\n \n \n 21/04/09 \n \n \n BioInvent International AB Annual General Meeting \n \n
\n \n \n 20/03/09 \n \n \n Annual General Meeting in BioInvent International AB \n \n
\n \n \n 27/02/09 \n \n \n BioInvent Presents Positive Preclinical Data for BI-505 in Myeloma \n \n
\n \n \n 23/02/09 \n \n \n BioInvent and ThromboGenics Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis \n \n
\n \n \n 26/01/09 \n \n \n BioInvent and ThromboGenics Receive Technology Transfer Success Fee from Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF) \n \n
\n \n \n 18/06/08 \n \n \n BioInvent and ThromboGenics announce a strategic alliance with Roche for TB-403, a novel anti-cancer antibody \n \n
\n \n \n 03/06/08 \n \n \n BioInvent and ThromboGenics report positive Phase I results for anti-PlGF cancer therapeutic TB-403 \n \n
\n \n \n 14/04/08 \n \n \n BioInvent International AB Annual General Meeting \n \n
\n \n \n 13/03/08 \n \n \n Annual General Meeting in Bioinvent International AB \n \n
\n \n \n 12/03/08 \n \n \n BioInvent signs deal with Bayer HealthCare for the discovery and development of therapeutic antibodies. \n \n
\n \n \n 18/01/08 \n \n \n BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer \n \n
\n \n \n 15/01/08 \n \n \n BioInvent and Genentech Initiate Phase I Clinical Trial for BI-204, a potential treatment for cardiovascular conditions associated with atherosclerosis. \n \n
\n \n \n 11/12/07 \n \n \n Results of the Phase I Trial of TB-402 Presented at the Prestigious American Society of Hematology Annual Meeting \n \n
\n \n \n 05/12/07 \n \n \n BioInvent Designates Drug Candidate, BI-505, for the Treatment of Cancer \n \n
\n \n \n 02/11/07 \n \n \n BioInvent and ThromboGenics Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell \n \n
\n \n \n 07/09/07 \n \n \n ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402 \n \n
\n \n \n 05/07/07 \n \n \n Directed Issue approved at Extraordinary General Meeting \n \n
\n \n \n 19/06/07 \n \n \n BioInvent implements a directed new share issue worth SEK 125 million and summons to an extraordinary shareholders\' meeting \n \n
\n \n \n 29/05/07 \n \n \n Bioinvent updates project portfolio \n \n
\n \n \n 17/04/07 \n \n \n BioInvent International AB Annual General Meeting \n \n
\n \n \n 15/03/07 \n \n \n Annual General Meeting of Shareholders in BioInvent International AB \n \n
\n \n \n 12/02/07 \n \n \n BioInvent and ThromboGenics Receive Approval to Begin Clinical Trials for Anticoagulant TB-402 \n \n
\n \n \n 12/01/07 \n \n \n BioInvent enters collaboration with Genentech to develop and commercialize BioInvent\'s proprietary antibody for the potential treatment of cardiovascular diseases \n \n
\n \n \n 28/12/06 \n \n \n BioInvent and ThromboGenics Awarded Euro 2 Million EU Grant for ANGIOSTOP Anti-Angiogenesis Programme \n \n
\n \n \n 13/07/06 \n \n \n BioInvent updates status within the HIV project \n \n
\n \n \n 29/05/06 \n \n \n BioInvent reports the result from the clinical study in HIV \n \n
\n \n \n 24/04/06 \n \n \n BioInvent International AB Annual General Meeting \n \n
\n \n \n 03/04/06 \n \n \n BioInvent and Immusol to collaborate on antibody therapeutic for macular degeneration \n \n
\n \n \n 27/03/06 \n \n \n Annual General Meeting in BioInvent International AB publ) \n \n
\n \n \n 16/02/06 \n \n \n BioInvent reassigns rights to develop osteoarthritis drugs to Cartela \n \n
\n \n \n 11/01/06 \n \n \n BioInvent Issued US Patent for n-CoDeR® Antibody Library \n \n
\n \n \n 09/12/05 \n \n \n BioInvent\'s preferential rights issue is oversubscribed \n \n
\n \n \n 14/11/05 \n \n \n BioInvent and Lund University present data on significant plaque reduction in blood vessels \n \n
\n \n \n 08/11/05 \n \n \n BioInvent\'s Nomination Committee appointed \n \n
\n \n \n 02/11/05 \n \n \n Preference Issue approved at Extraordinary General Meeting \n \n
\n \n \n 17/10/05 \n \n \n Notice of Extraordinary General Meeting 2 Nov, 2005 \n \n
\n \n \n 13/10/05 \n \n \n BioInvent takes an important step in the continued development of its drug candidates and implements a secured issue of shares worth SEK 160 million with preferential rights \n \n
\n \n \n 20/06/05 \n \n \n BI-201 against HIV-infection has today been given to the first patients \n \n
\n \n \n 03/06/05 \n \n \n BioInvent and Cambridge Antibody Technology sign Licensing Agreement \n \n
\n \n \n 18/05/05 \n \n \n BioInvent\'s candidate drug against HIV/AIDS approved to enter clinical trials in UK \n \n
\n \n \n 16/05/05 \n \n \n BioInvent International AB Annual General Meeting \n \n
\n \n \n 11/05/05 \n \n \n European Patent granted on BioInvent\'s cancer project based on the receptor angiomotin \n \n
\n \n \n 18/04/05 \n \n \n Annual General Meeting of Shareholders in BioInvent International AB (publ) \n \n
\n \n \n 24/02/05 \n \n \n BioInvent presents data indicating no development of resistance in HIV project \n \n
\n \n \n 17/12/04 \n \n \n BioInvent and ThromboGenics Add New Anti-Angiogenesis Program to Collaboration \n \n
\n \n \n 28/09/04 \n \n \n BioInvent and ThromboGenics Strike Alliance to Jointly Develop Antibody-Based Therapeutics To Pursue Novel Treatments for Vascular Indications \n \n
\n \n \n 14/07/04 \n \n \n BioInvent and Cartela reach the first milestone in the development of drug to treat diseases of the joints \n \n
\n \n \n 24/06/04 \n \n \n BioInvent to Supply Critical Antibodies for Orbus Medical Technology\'s Innovative Genous Bio-engineered Surface \n \n
\n \n \n 17/05/04 \n \n \n BioInvent appoints head of clinical development \n \n
\n \n \n 22/04/04 \n \n \n BioInvent International AB Annual General Meeting \n \n
\n \n \n 23/03/04 \n \n \n Annual General Meeting of Shareholders in BioInvent International AB (publ) \n \n
\n \n \n 10/02/04 \n \n \n BioInvent and ALK-Abelló enter into agreement on commercial supply of antibodies \n \n
\n \n \n 26/11/03 \n \n \n BioInvent Issued European Patent for n-CoDeRÒ Antibody Library \n \n
\n \n \n 25/11/03 \n \n \n BioInvent Announces Cross-license of Antibody Technologies with XOMA \n \n
\n \n \n 16/10/03 \n \n \n BioInvent acquires the rights to develop a new drug to treat osteoarthritis \n \n
\n \n \n 23/09/03 \n \n \n BioInvent - reorganization finalized \n \n
\n \n \n 10/09/03 \n \n \n BioInvent reorganize \n \n
\n \n \n 10/04/03 \n \n \n BioInvent International AB Annual General Meeting \n \n
\n \n \n 11/03/03 \n \n \n Annual General Meeting of Shareholders in BioInvent International AB (publ) \n \n
\n \n \n 02/01/03 \n \n \n BioInvent exercises option to develop and commercialize a new type of drug to treat arteriosclerosis \n \n
\n \n \n 20/12/02 \n \n \n BioInvent and ImmunoGen extend collaboration \n \n
\n \n \n 12/12/02 \n \n \n BioInvent and Resistentia have reached a settlement \n \n
\n \n \n 09/12/02 \n \n \n BioInvent strengthens its management team \n \n
\n \n \n 05/12/02 \n \n \n BioInvent extends collaboration with Igeneon: New agreements for manufacturing of monoclonal antibody products \n \n
\n \n \n 08/10/02 \n \n \n BioInvent International AB (publ) appoints Vice President \n \n
\n \n \n 18/07/02 \n \n \n BioInvent acquires the rights to develop and commercialise a new type of drug against HIV \n \n
\n \n \n 10/06/02 \n \n \n Pharmacia Corporation and BioInvent enter into agreement on large-scale production of antibodies \n \n
\n \n \n 05/05/02 \n \n \n CellControl and BioInvent sign Phase III Manufacturing Agreement for ACA 125 Antibody \n \n
\n \n \n 02/05/02 \n \n \n Annual General Meeting of BioInvent International AB \n \n
\n \n \n 14/03/02 \n \n \n OGS and BioInvent form Therapeutic Antibodies Alliance \n \n
\n \n \n 05/03/02 \n \n \n BioInvent releases new human antibody library, n-CoDeR-Fab \n \n
\n \n \n 22/02/02 \n \n \n BioInvent extends collaboration with GlaxoSmithKline Biologicals \n \n
\n \n \n 20/12/01 \n \n \n Resistentia Pharmaceuticals AB cancels agreement with BioInvent for process development and production of allergy vaccine \n \n
\n \n \n 15/10/01 \n \n \n BioInvent strengthens management team with appointment of Jonas Källmén as Chief Financial Officer \n \n
\n \n \n 28/06/01 \n \n \n ImmunoGen & BioInvent - Sign Antibody Manufacturing Agreement \n \n
\n \n \n 07/06/01 \n \n \n BioInvent International AB will be listed on June 12 - The Offering was subscribed to 2.5 times \n \n
\n \n \n 17/05/01 \n \n \n Announces Flotation on the O-list of the Stockholm Exchange \n \n
\n \n \n 15/05/01 \n \n \n BioInvent International AB announces third customer for n-CoDeR \n \n
\n \n \n 11/04/01 \n \n \n Antisoma and BioInvent sign BC-1 monoclonal antibody manufacturing agreement \n \n

\n \n');